- Email:
Microglia Differentiation Service
Introduction
Microglia differentiation generates physiologically relevant human microglia from pluripotent stem cells and recapitulates key features of brain-resident immune cells. It supports neuro-immune modeling, synaptic function analysis, and predictive drug evaluation. Creative Biolabs provides high-purity, functionally mature TMEM119+/P2RY12+ human microglia via advanced iPSC-based protocols. These stable, responsive cells enable reliable neuroinflammation research, drug screening, and target validation.
Discover How We Can Help - Request a Consultation →
Microglia Differentiation Service
Microglia are the resident innate immune cells of the central nervous system, responsible for immune surveillance, synaptic pruning, debris clearance, and inflammatory regulation. Dysfunction and abnormal activation of microglia are closely associated with neurodegenerative diseases, neuroinflammation, stroke, neurodevelopmental disorders, and psychiatric conditions.
Key Features
- Derived from human iPSCs/ESCs under defined, xeno-free, feeder-free conditions
- Uses optimized small-molecule induction for efficient microglial specification
- Generates mature, functional IBA1+ TMEM119+ P2RY12+ microglia with high purity
- Shows typical branched/ameboid morphology and non-tumorigenic properties
- Stable batch consistency and suitable for long-term culture and co-culture
Service Content
- Differentiation from pluripotent stem cells to myeloid progenitor cells
- Directed differentiation and maturation into functional microglia
- Inflammatory activation model (M1/M2 phenotype induction) available
- Quality validation: immunofluorescence, qPCR, Western blot, flow cytometry
- Optional: phagocytosis assay, co-culture with neurons/astrocytes, cytokine detection
Related Diseases & Mechanisms
| Disease | Mechanism Involving Microglia |
|---|---|
| Alzheimer's Disease | Abnormal activation, impaired Aβ phagocytosis, and neuroinflammation |
| Parkinson's Disease | α-synuclein aggregation, pro-inflammatory factor release, neuronal toxicity |
| Multiple Sclerosis | Myelin phagocytosis, inflammatory infiltration, and blood-brain barrier damage |
| Stroke / Ischemia | Ischemic activation, debris clearance disorder, secondary neuroinflammation |
| Autism & Neurodevelopmental Disorders | Abnormal synaptic pruning, immune microenvironment disorder |
Applications
- Neurological disease modeling and mechanism research
- High-throughput drug screening and anti-neuroinflammatory evaluation
- Glia-neuron interaction and synaptic function studies
- Neuroinflammation and microglial activation research
- Toxicity testing and target validation for CNS drug discovery
Workflow
Our professional differentiation service is a streamlined, industrial-grade process that ensures maximum yield and phenotypic stability.
What We Can Offer
At Creative Biolabs, we provide a professional-grade Microglia Differentiation platform tailored to the rigorous demands of the global biopharmaceutical industry. Our service is not just a protocol; it is an industrial-scale biological solution.
One-Stop Custom Differentiation Service
From initial iPSC reprogramming and CRISPR/Cas9 gene editing to pilot-scale and large-scale manufacturing of assay-ready microglia.
Scale and Capability
Large-scale industrial production capabilities delivering over 109 high-purity microglia per batch to support high-throughput screening (HTS) campaigns.
Genetic Customization
Optimization of disease-specific phenotypes through expert CRISPR engineering, allowing for the study of rare variants or patient-specific backgrounds.
Industrial Quality Systems
Integration of Quality-by-Design (QbD) and Process Analytical Techniques (PAT) to ensure batch-to-batch consistency and phenotypic stability.
Strict Aseptic Verification
All-side testing for mycoplasma, endotoxins, and sterility throughout the maturation and harvest process.
Flexible Culture Modes
Ability to run differentiation in monolayer, 3D spheroid, or specialized microfluidic organ-on-a-chip environments.
High-Standard QC Tools
Utilization of advanced single-cell RNA sequencing (scRNA-seq) and high-content imaging to quantify and evaluate the physiological relevance of every cell lot.
Experience the Creative Biolabs Advantage - Get a Quote Today →
Case Study
A study aimed to establish a kit-free, hypoxia-independent, and sorting-free reproducible protocol for generating iPSC-derived microglia (iMG) that mimics native microglial ontogeny.
The research induced iPSCs into iMG through stepwise primitive hematopoiesis and microglial specification, monitoring morphological changes via brightfield microscopy. Identity and purity were validated using IBA1 immunolabeling, qPCR analysis of microglial markers (HEXB, P2RY12, TMEM119), and pluripotency gene downregulation (NANOG, PODXL, POU5F1), and flow cytometry for CD34+/CD43+ progenitors. High-content imaging confirmed >98% of cells expressed P2RY12, PU.1, and TREM2.
These results confirm the successful generation of well-defined, high-purity iMG from novel iPSC lines using the optimized stepwise protocol.
Fig.1 iPSCs differentiated into iMG and verified via morphology, staining, qPCR and flow cytometry.1
Customer Reviews
FAQs
Q: How do your iPSC-derived microglia compare to primary human microglia?
A: Our iMGs express the core homeostatic markers (TMEM119, P2RY12) and follow the yolk sac development pathway, showing high transcriptomic correlation with primary human cells without the ethical or supply constraints of post-mortem tissue.
Q: Can you generate microglia from our own patient-derived iPSC lines?
A: Yes, we offer a "Starting Material" service where we can differentiate your provided lines or perform reprogramming and CRISPR editing on-site to create custom disease models.
Q: What functional assays are included in the validation phase?
A: Standard validation includes flow cytometry for Iba-1/CD11b, pH-sensitive bead phagocytosis, and multi-plex cytokine release (IL-6, TNF, IL-1β) in response to LPS or other inflammogens.
Q: Are these cells suitable for 3D co-culture or organoid integration?
A: Yes. Our protocols are optimized for integration into 3D environments, including brain organoids and BBB-on-a-chip models, where they exhibit natural ramification and surveillance behavior.
Q: What is the shelf-life and recovery rate of the cryopreserved cells?
A: Our cells are cryopreserved using specialized media that ensures >90% viability upon thawing. We provide detailed recovery protocols to ensure the cells regain their homeostatic morphology within 24-48 hours.
Creative Biolabs offers an end-to-end solution for your neuroinflammation research, from custom CRISPR-edited iPSC lines to functionally validated, assay-ready microglial populations. Our expertise ensures that your project benefits from the most human-relevant models available today, reducing developmental risk and accelerating your path to the clinic.
Contact Our Team for More Information and to Discuss Your Project →
Reference
- Haskell, Angela K., et al. "Generation and characterization of iPSC‐derived microglia for in vitro modeling of stimuli‐specific neuroimmune responses." Alzheimer's & Dementia 22.2 (2026): e71117. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1002/alz.71117.
For Research Use Only. Not For Clinical Use.